IDEXX LABORATORIES INC

IDEXX Laboratories posts Q2 earnings beat, driven by organic growth in companion‑animal, water and livestock diagnostics, raising EPS and revenue guidance while boosting AI‑driven diagnostics.

Veterinary point‑of‑care diagnostics: Asia Pacific leads a 10‑year growth trend powered by rapid, portable tech and consumable innovation for faster, accurate animal health decisions.

Explore how IDEXX Laboratories’ board moves, AI‑driven diagnostics and operational resilience fuel its $45B market‑cap and 20%+ ROI in a value‑based healthcare environment.

Pet‑health spending climbs 8% as owners favor premium diagnostics & pharma, not routine visits—driven by younger, tech‑savvy buyers and longer pet lifespans.

IDEXX Laboratories jumps to 113th on the S&P 500 analyst pick list—analyzing why its veterinary diagnostics, AI innovations, and regulatory shifts are reshaping investor sentiment.

Explore how IDEXX Laboratories is driving growth in veterinary diagnostics with AI‑powered testing, rapid point‑of‑care solutions, and strong financials.

CEO and senior director insider sale on Nasdaq: how this March 17 trade impacts stock value and investor sentiment

Explore IDEXX Laboratories’ growth strategy, international expansion, and how its data‑driven diagnostics aim to win value‑based reimbursement and boost earnings.

Explore how IDEXX Laboratories thrives amid market swings, leveraging digital diagnostics, regulatory demand, and diversification across veterinary, food, and water testing.

Idexx Laboratories expands its global veterinary diagnostics reach, driving $1.12 bn revenue growth and 9.8% CAGR in companion‑animal health with AI‑powered POC tests, improved reimbursement models, and strong financial health.